Home›Companies›Biotech & Pharma›Potentiam

Potentiam Biosciences, Inc.

Potentiam applies artificial intelligence to find and develop targets for new medicines.

Updated Nov 16, 2026·Latest SEC filing Nov 16, 2026·Suggest an edit

About Potentiam

Potentiam uses artificial intelligence to find targets for new medicines. Its platforms are designed to identify and develop those targets.

Potentiam is based in Irving, Texas. Peppi Prasit is chief executive officer. Bruce Beutler is chairman and president. He also serves as secretary and sole director.

Funding Rounds (SEC Form D)

First saleFiled with SECAmount soldInvestorsAvg. checkTermsFiling
Nov 3, 2026Nov 16, 2026$250,000target not set1$250KOptions, Securities on exercise, Simple Agreement for Future Equity (SAFE)Rule 506(b)Form D ↗

First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.

Leadership Team

Executive officers and directors listed on Potentiam's Form D filed Nov 16, 2026.

BB
Bruce Beutler
Sole Director; Chairman, President and Secretary
PP
Peppi Prasit
Chief Executive Officer

Why Investors Backed Potentiam

Potentiam's view is that some therapeutic targets remain hard to find. Its AI-powered platforms are designed to identify and develop new targets. [1]

We wrote this summary from public statements by Potentiam and its investors. It is not investment advice.

Sources

  1. CompanyPotentiam website · linked above ↑
  2. SECPotentiam Form D, filed 2026-11-16 · linked above ↑
  3. SECPotentiam Biosciences, Inc. filing history